Australia, Oct. 28 -- Cytospire Therapeutics Ltd., owns the trademark (2683801) for 'CYTOSPIRE' till June 26, 2036.

Status: protected: Registered/protected

Classes: 5 [Pharmaceutical preparations; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the prevention and treatment of cancer and tumours; pharmaceutical preparations for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; biological preparations for medical purposes; biological preparations for the prevention and treatment of cancer and tumours; biological preparations for use in the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; biological preparations for use in the prevention and treatment of cancer and tumours; biopharmaceuticals for the treatment of cancer; antibodies; diagnostic reagents for medical use.] and 42 [Scientific and technological services; scientific research; pharmaceutical research and development services; medical research services; drug development services; laboratory analysis; laboratory research; laboratory testing; testing of pharmaceuticals; pharmaceutical research and development services in the field of oncology and immunotherapy; pharmaceutical research and development of pharmaceuticals and drugs for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; medical research services in the field of oncology and immunotherapy; medical research services for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; drug development services in the field of oncology and immunotherapy; drug development services for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; laboratory research and testing of pharmaceuticals in the field of oncology and immunotherapy; laboratory research and testing of pharmaceuticals for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; research and development services in the field of antibodies; research and development in the field of biotechnology; development of antibodies; development of antibodies for use in the field of oncology and immunotherapy; information, consultancy and advice in relation to the aforesaid services.]

Type of Mark: Word

Date of Acceptance: Aug. 20

Registration Advertised: Oct. 27

For further details contact Banki Haddock Fiora and CMS Cameron McKenna Nabarro Olswang LLP .

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2683801.

Disclaimer: Curated by HT Syndication.